Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

6 Oct 2016 11:43

RNS Number : 8959L
PuriCore Plc
06 October 2016
 

 

PuriCore plc

("PuriCore" or the "Company")

 

Result of General Meeting

 

 

6 October 2016 - PuriCore plc (AIM: PURI), the emerging specialty biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, announced on 20 September 2016 it had agreed to sell the Group's Supermarket Retail Business, subject to Shareholder approval and other customary requirements, to Chemstar Corp.

 

The Company is pleased to announce that the Resolution, as set out in the notice of general meeting contained within the Circular to Shareholders, approving the Disposal was duly passed at the general meeting held today. Completion of the Disposal is expected tomorrow and a further announcement will be made in due course.

 

Enquiries:

 

PuriCore plc

+44 (0) 20 3727 1000

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

FTI Consulting

+44 (0) 20 3727 1000

Simon Conway / Mo Noonan

N+1 Singer (Nominated Adviser and Broker)

+44 (0) 20 7496 3000

Aubrey Powell / Jen Boorer

 

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014 (MAR).

 

Unless otherwise indicated, capitalised terms in this announcement have the same definition as in the Circular.

 

About PuriCore

 

PuriCore is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated a drug development programme, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes their formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology, Ophthalmology and potentially rare diseases. For more details, go to the Company's website: www.puricore.com

 

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROMDMMGGGVZGVZM
Date   Source Headline
11th Jun 20072:32 pmRNSPresenting at Conference
11th Jun 200712:18 pmRNSHolding(s) in Company
31st May 200710:14 amRNSResult of AGM
23rd May 200712:00 pmBUSFDA Lists Sterilox Food Safety Solution for Food Contact
23rd May 20077:02 amRNSRe: Food Safety Solution
21st May 200712:00 pmBUSStudy Shows PuriCore's Aquatine(TM) EC Effective for Root Canal Disinfecting and Cleansing
14th May 20075:57 pmRNSAnnual Information Update
25th Apr 20079:14 amRNSDirector/PDMR Shareholding
19th Apr 200710:45 amRNSHolding(s) in Company
19th Apr 20079:54 amRNSDirector/PDMR Shareholding
18th Apr 20074:00 pmRNSHolding(s) in Company
18th Apr 20077:01 amRNSDirector/PDMR Shareholding
16th Apr 20077:02 amRNSFinal Results
5th Apr 200712:00 pmBUSPuriCore Receives FDA 510(k) Approval for Endoscope Disinfectant System in US
5th Apr 20077:01 amRNSFDA 510(k) Approval
29th Mar 20078:00 amRNSNotice of Results
27th Mar 20071:54 pmBUSPuriCore signs additional endoscope reprocessor marketing partnership
27th Mar 20071:02 pmRNSSigns Marketing Partnership
5th Mar 20075:12 pmRNSHolding(s) in Company
5th Feb 20077:01 amRNSRe Agreement
5th Feb 20077:01 amRNSTrading Update
26th Jan 20073:44 pmRNSRe: Section 198
8th Jan 20077:00 amRNSFundraising
18th Dec 20064:01 pmRNSTransparency Rule
8th Dec 20062:00 pmRNSGreg Bosch Wins CEO of Year
13th Nov 20067:02 amRNSAppointment
7th Nov 20063:47 pmRNSRe Interest in Shares
7th Nov 20063:44 pmRNSInterest in Shares
13th Sep 20067:03 amRNSAppointments
13th Sep 20067:03 amRNSContract
13th Sep 20067:03 amRNSInterim Results
21st Aug 200611:05 amRNSHolding(s) in Company
16th Aug 200611:12 amRNSNotice of Results
7th Aug 20063:43 pmRNSBlocklisting Applications

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.